

COVID-19 Information[Public health information \(CDC\)](#)[Research information \(NIH\)](#)[SARS-CoV-2 data \(NCBI\)](#)[Prevention and treatment information \(HHS\)](#)[Español](#)

FULL TEXT LINKS

[> Biochem Biophys Res Commun](#). 2021 Aug 20;566:164-169. doi: 10.1016/j.bbrc.2021.06.019.

Epub 2021 Jun 11.

[HHS Vulnerability Disclosure](#)

PEA prevented early BBB disruption after cerebral ischaemic/reperfusion (I/R) injury through regulation of ROCK/MLC signaling

Dequan Kong ¹, Baoying Xie ², Yuhang Li ³, Yaping Xu ⁴

Affiliations

PMID: 34126347 DOI: [10.1016/j.bbrc.2021.06.019](#)

Abstract

Palmitoylethanolamide (PEA) offers a strong protection against BBB disruption and neurological deficits after cerebral ischaemic/reperfusion (I/R) injury. To date, these BBB protective effects of PEA are mainly attributed to PPAR α -mediated actions. However, whether PEA protects against BBB disruption through direct regulation of cytoskeletal microfilaments remains unknown. Here, we identified PEA as a Rho-associated protein kinase (ROCK2) inhibitor ($IC_{50} = 38.4 \pm 4.8 \mu M$). In vitro data suggested that PEA reduced the activation of ROCK/MLC signaling and stress fiber formation within microvascular endothelial cells (ECs) after oxygen-glucose deprivation (OGD), and consequently attenuated early (0–4 h) EC barrier disruption. These actions of PEA could not be blocked by the PPAR α antagonist GW6471. In summary, the present study described a previously unexplored role of PEA as a ROCK2 inhibitor, and propose a PPAR α -independent mechanism for pharmacological effects of PEA.

Keywords: Blood–brain barrier (BBB); Cerebral ischaemic; Myosin light chain (MLC); Palmitoylethanolamide (PEA); Reperfusion (I/R) injury; Rho-associated protein kinase (ROCK).

Copyright © 2021 Elsevier Inc. All rights reserved.

Related information

[MedGen](#)[PubChem Compound \(MeSH Keyword\)](#)

LinkOut – more resources

[Full Text Sources](#)[Elsevier Science](#)